WO2026018154 - COMBINATIONS OF SABCOMELINE WITH NON-CNS PENETRANT MUSCARINIC ANTAGONISTS
National phase entry is expected:
Publication Number
WO/2026/018154
Publication Date
22.01.2026
International Application No.
PCT/IB2025/057154
International Filing Date
15.07.2025
Title **
[English]
COMBINATIONS OF SABCOMELINE WITH NON-CNS PENETRANT MUSCARINIC ANTAGONISTS
[French]
ASSOCIATIONS DE SABCOMÉLINE ET D’ANTAGONISTES MUSCARINIQUES NE PÉNÉTRANT PAS DANS LE SNC
Applicants **
SYREMIS THERAPEUTICS LTD.
Inventors
MAWASI, Hafiz
Priority Data
63/672,123
16.07.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2023 | |
| EPO | Filing, Examination, Granting | 8159 | |
| Japan | Filing, Examination, Granting | 2170 | |
| South Korea | Filing, Examination, Granting | 2051 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
19,143
Contact Us
Abstract[English]
The invention relates to a combination of sabcomeline, or a pharmaceutically acceptable salt thereof, and a non-Central Nervous System penetrant muscarinic antagonist, wherein the daily dose provided by the combination of the non-Central Nervous System penetrant muscarinic antagonist is no more than 20 mg. The invention further relates to pharmaceutical compositions comprising the combination of sabcomeline, or a pharmaceutically acceptable salt thereof, and a non-Central Nervous System penetrant muscarinic antagonist and uses thereof.[French]
L'invention concerne une association de sabcoméline, ou d'un sel pharmaceutiquement acceptable de celle-ci, et d'un antagoniste muscarinique ne pénétrant pas dans le système nerveux central, la dose journalière apportée par l’association de l'antagoniste muscarinique ne pénétrant pas dans le système nerveux central n'étant pas supérieure à 20 mg. L'invention concerne en outre des compositions pharmaceutiques comprenant l’association de sabcoméline, ou d'un sel pharmaceutiquement acceptable de celle-ci, et d'un antagoniste muscarinique ne pénétrant pas dans le système nerveux central et leurs utilisations.